Dental Pharmacology: Analgesics, Antibiotics, and Drug Interactions in Clinical Practice

Pharmacological competence is an essential component of contemporary dental practice, as dental professionals routinely prescribe, administer, and manage a wide array of medications across diverse patient populations. Analgesics and antibiotics constitute the most frequently prescribed drug classes in dentistry, and their safe and effective use requires a thorough understanding of pharmacokinetics, pharmacodynamics, adverse effect profiles, and clinically significant drug interactions. Furthermore, the increasing prevalence of polypharmacy among aging and medically complex patient populations has elevated the importance of medication reconciliation and interaction screening as integral components of the dental treatment planning process. This article provides a comprehensive overview of analgesics, antibiotics, and drug interactions relevant to everyday dental practice.

Analgesics in Dental Practice

Non-Steroidal Anti-Inflammatory Drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line analgesic agents for most dental pain of inflammatory origin, owing to their combined analgesic, anti-inflammatory, and antipyretic properties. Ibuprofen, available over the counter in doses up to 400 mg and by prescription at 600–800 mg, is the most extensively studied NSAID in the dental context and serves as the benchmark against which other analgesics are compared. Clinical trials have consistently demonstrated that ibuprofen 400 mg provides superior analgesia to acetaminophen 1000 mg and codeine 60 mg for moderate to severe dental pain, with a favorable safety profile when used for short durations at recommended doses.

The mechanism of action of NSAIDs involves the inhibition of cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins that mediate inflammation, pain, and fever. Cyclooxygenase exists in two primary isoforms: COX-1, constitutively expressed in most tissues and responsible for maintaining gastric mucosal integrity, platelet function, and renal perfusion, and COX-2, inducible at sites of inflammation. Traditional NSAIDs such as ibuprofen, naproxen, and diclofenac inhibit both isoforms non-selectively, accounting for both their therapeutic effects and their gastrointestinal, renal, and hematologic adverse effects. Selective COX-2 inhibitors, including celecoxib, were developed to provide anti-inflammatory efficacy with reduced gastrointestinal toxicity, though their use is tempered by cardiovascular safety concerns associated with prolonged administration.

Acetaminophen

Acetaminophen (paracetamol) is a centrally acting analgesic and antipyretic that, unlike NSAIDs, lacks significant anti-inflammatory activity and does not inhibit peripheral cyclooxygenase. Its mechanism of action is not fully elucidated but is thought to involve central COX inhibition, interaction with the serotonergic descending pain pathway, and modulation of the endocannabinoid system. Acetaminophen is an essential component of the dental analgesic armamentarium, particularly for patients with contraindications to NSAIDs, including those with peptic ulcer disease, bleeding disorders, renal impairment, or aspirin-exacerbated respiratory disease. The maximum recommended daily dose of 3000 mg (reduced from 4000 mg in many guidelines) must be strictly observed to avoid hepatotoxicity, with particular caution in patients with hepatic impairment, chronic alcohol consumption, or malnutrition.

Opioid Analgesics

The role of opioid analgesics in dental practice has undergone significant re-evaluation in response to the global opioid epidemic. Current evidence and professional guidelines advocate for NSAIDs and acetaminophen as first-line agents for acute dental pain, reserving opioids for cases of severe pain refractory to non-opioid therapy. When opioid analgesia is deemed necessary, the prescription should be for the lowest effective dose, for the shortest duration required to manage acute pain, and in limited quantities that reflect the expected duration of severe pain following the dental procedure.

Codeine, a prodrug requiring CYP2D6-mediated conversion to morphine for analgesic activity, has diminished in popularity due to its unpredictable efficacy—approximately 7–10% of the population are poor metabolizers with CYP2D6 deficiency and derive minimal analgesia, while ultra-rapid metabolizers are at risk of toxicity from excessive morphine production. Tramadol, a weak mu-opioid receptor agonist that also inhibits serotonin and norepinephrine reuptake, provides moderate analgesia for dental pain but carries risks of serotonin syndrome when combined with other serotonergic medications and has abuse potential.

Combination Analgesia

The combination of ibuprofen and acetaminophen has emerged as a particularly effective analgesic strategy for acute dental pain. Systematic reviews and meta-analyses have demonstrated that the ibuprofen-acetaminophen combination provides superior analgesia to either agent alone, including combinations containing opioids, and is associated with fewer adverse effects. A typical regimen of ibuprofen 400–600 mg and acetaminophen 500–1000 mg administered at staggered intervals or simultaneously achieves effective, sustained pain control for most dental procedures.

Antibiotics in Dental Practice

Indications and Principles

Antibiotics in dentistry are indicated for the treatment of odontogenic infections and, in selected circumstances, for antibiotic prophylaxis against infective endocarditis and prosthetic joint infection. The vast majority of dental infections can be managed effectively with local measures—incision and drainage, pulp extirpation, or extraction—without the need for systemic antibiotics. Antibiotics should be reserved for cases with evidence of systemic involvement, including fever, lymphadenopathy, trismus, rapidly spreading infection, or infection in immunocompromised patients.

The microbiology of odontogenic infections is typically polymicrobial, involving a mixture of facultative and obligate anaerobic bacteria. Streptococci, particularly the Streptococcus milleri group, represent the predominant aerobic species, while Peptostreptococcus, Prevotella, Porphyromonas, and Fusobacterium species are common anaerobic isolates. Empiric antibiotic therapy should provide coverage against this mixed flora, with the specific agent selected based on infection severity, patient allergy history, and local resistance patterns.

First-Line Agents

Phenoxymethylpenicillin (penicillin V) remains the first-line antibiotic for odontogenic infections in the absence of penicillin allergy, owing to its favorable spectrum of activity against oral streptococci and anaerobes, safety profile, and low cost. Amoxicillin offers improved oral bioavailability and a slightly broader spectrum, making it a popular alternative. The addition of clavulanic acid (co-amoxiclav) extends coverage against beta-lactamase-producing bacteria, which are increasingly prevalent in odontogenic infections and include species such as Prevotella and Fusobacterium.

For patients with penicillin allergy, clindamycin provides effective coverage against both aerobic streptococci and anaerobic bacteria, though its use is associated with an elevated risk of Clostridioides difficile colitis. Metronidazole, effective against obligate anaerobes but lacking activity against aerobic and facultative organisms, is typically used in combination with penicillin or amoxicillin for severe infections. Azithromycin and clarithromycin, macrolide antibiotics, represent alternative options for penicillin-allergic patients, though rising resistance rates in oral streptococci warrant caution.

Duration and Stewardship

Antimicrobial stewardship principles dictate that antibiotic courses should employ the narrowest effective spectrum, the shortest effective duration, and appropriate dosing to achieve therapeutic concentrations at the site of infection. For most acute odontogenic infections, a 5-day course is sufficient when combined with definitive local treatment. Extended courses beyond 7 days are rarely indicated and contribute to antimicrobial resistance without providing additional clinical benefit. Dental practitioners play a critical role in antimicrobial stewardship, as dental prescribing accounts for a significant proportion of community antibiotic use and has been associated with the emergence of resistant organisms including Clostridioides difficile.

Clinically Significant Drug Interactions

Anticoagulants and Antiplatelet Agents

The management of patients receiving anticoagulant and antiplatelet therapy is among the most challenging pharmacological considerations in dental practice. NSAIDs are generally contraindicated in patients taking warfarin due to the additive bleeding risk from platelet inhibition and the potential for NSAID-induced gastropathy and displacement of warfarin from protein binding sites. COX-2 selective inhibitors also interact with warfarin and should be avoided. Acetaminophen is the analgesic of choice in these patients, though high doses exceeding 2000 mg daily may potentiate warfarin effect and should be used with monitoring.

Direct oral anticoagulants including dabigatran, rivaroxaban, apixaban, and edoxaban present fewer dietary and drug interactions than warfarin, but NSAIDs should still be used with caution due to additive antiplatelet effects and increased gastrointestinal bleeding risk. Dual antiplatelet therapy following coronary stent placement represents a particularly high-risk scenario in which NSAIDs are contraindicated and dental procedures should be coordinated with the patient's cardiologist.

Medication-Related Osteonecrosis of the Jaw

Antiresorptive and antiangiogenic medications, including bisphosphonates, denosumab, and tyrosine kinase inhibitors, are associated with medication-related osteonecrosis of the jaw (MRONJ), a serious complication characterized by exposed, non-healing bone in the maxillofacial region. The risk of MRONJ is highest with intravenous bisphosphonates used in oncology settings and considerably lower with oral bisphosphonates prescribed for osteoporosis. Dental practitioners must identify patients taking these medications, complete necessary dental treatment prior to initiating therapy when possible, and coordinate with the prescribing physician regarding the risks and timing of invasive dental procedures.

Polypharmacy in the Elderly

The elderly population, who constitute a growing proportion of dental patients, frequently present with polypharmacy, defined as the concurrent use of five or more medications. Polypharmacy substantially increases the risk of adverse drug reactions, drug interactions, and medication-related xerostomia, which in turn predisposes patients to caries, periodontal disease, and oral candidiasis. Medications commonly associated with xerostomia include anticholinergics, antidepressants, antihypertensives, diuretics, and antihistamines. Dental practitioners should perform thorough medication reconciliation at each visit and remain vigilant for signs of adverse drug effects manifesting in the oral cavity.

Conclusion

Pharmacological knowledge is fundamental to the safe and effective practice of dentistry. NSAIDs, alone or in combination with acetaminophen, should be the first-line approach to acute dental pain, with opioids reserved for refractory cases and prescribed under strict stewardship principles. Antibiotic therapy should be targeted, evidence-based, and employed judiciously in conjunction with definitive local treatment. Comprehensive medication review and awareness of clinically significant drug interactions, particularly those involving anticoagulants, antiresorptive agents, and polypharmacy in the elderly, are essential for minimizing adverse outcomes. By integrating pharmacological principles into everyday clinical decision-making, dental practitioners can optimize therapeutic outcomes while safeguarding patient safety.